DEBORAH J ANDREWS
CIK 1325697 · Interim Co-CEO and CFO · last filed 2026-05-19
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$341.0K
Companies
3
Total Filings
54
Lifetime Open-Market Net
-$6.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 4 of 6
54 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-08-26 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Buy (P) | +2,000 | $5.6K | EDGAR |
| 2015-07-06 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-07-03 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-09-04 | STAA | Mixed | — | -$408.3K | EDGAR |
| 2013-08-22 | STAA | Mixed | — | -$258.1K | EDGAR |
| 2013-08-19 | STAA | Mixed | — | -$46.1K | EDGAR |
| 2013-08-19 | STAA | Mixed | — | -$37.3K | EDGAR |
| 2013-08-19 | STAA | Mixed | −1,370 | -$10.7K | EDGAR |
| 2013-08-15 | STAA | Sell (S) | −3,928 | -$45.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.